trial

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

NCTId NCT04959201
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 90 (estimated)
Sponsored by China Medical University Hospital
Primary completion 2026-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
90 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2020-11-30
Primary completion
2026-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
NMDAE plus AO

Sponsors

China Medical University HospitalLead Sponsor
Ministry of Science and Technology, TaiwanCollaborator

Sites

1 total
Taichung, Taiwan

Linked catalysts

1
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia — primary completion2026-12

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE2
Primary Completion Date
2026-12
Status
RECRUITING
relationships
The graph out of here
drug
NMDAE plus AO
drug
lead_sponsor
China Medical University Hospital
company
collaborator
Ministry of Science and Technology, Taiwan
company
indication
Schizophrenia
indication
Schizophrenia
indication